A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis
This trial is active, not recruiting.
|Treatments||122-0551 foam, vehicle foam|
|Start date||January 2015|
|End date||September 2015|
|Trial size||140 participants|
|Trial identifier||NCT02367911, 122-0551-305|
This Phase 3 study has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Birmingham, AL||Total Skin and Beauty Dermatology Center, PC||no longer recruiting|
|Ormond Beach, FL||Leavitt Medical Associates of Florida d/b/a Ameriderm Research||no longer recruiting|
|Carmel, IN||Shideler Clinical Research Center||no longer recruiting|
|Plainfield, IN||The Indiana Clinical Trials Center, PC||no longer recruiting|
|Detroit, MI||Henry Ford Health System||no longer recruiting|
|High Point, NC||Dermatology Consulting Services||no longer recruiting|
|Arlington, TX||Arlington Research Center, Inc.||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, investigator)|
Proportion of subjects rated a "treatment success" based on the Investigator's Global Assessment (IGA)
time frame: Day 15
Proportion of subjects rated a "treatment success" for each of the clinical signs of psoriasis (scaling, erythema and plaque elevation)
time frame: Day 15
Male or female participants at least 18 years old.
Inclusion Criteria: - Subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 2% and no more than 12% affected body surface area. - Subject has an Investigator's Global Assessment (IGA) score of at least three (moderate) at study start. - If subject is a woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control for the duration of the study. Exclusion Criteria: - Subject has spontaneously improving or rapidly deteriorating plaque psoriasis. - Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis. - Subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis, or which exposes the subject to an unacceptable risk by study participation. - Subject has used any phototherapy (including laser), photo-chemotherapy or other forms of photo based therapy for the treatment of their psoriasis within 30 days prior to study start. - Subject has used any systemic methotrexate, retinoids, systemic corticosteroids [including intralesional, intra-articular, and intramuscular corticosteroids], cyclosporine or analogous products within 90 days prior to study start. - Subject has used any systemic biologic therapy (i.e., FDA-approved or experimental therapy) within five half-lives of the biologic prior to study start.
|Official title||A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis|
Call for more information